Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IKT Inhibikase Therapeutics, Inc.

交易中 10-12 15:11:19 EDT

1.81

-0.16

-8.12%

最高1.95	最低1.77	成交量49.34万
今开1.95	昨收1.97	日振幅9.14%
总市值2.53亿	流通市值1.17亿	总股本1.40亿
成交额90.94万	换手率0.76%	流通股本6,452万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IKT","market":"US","secType":"STK","nameCN":"Inhibikase Therapeutics, Inc.","latestPrice":1.81,"timestamp":1791832273850,"preClose":1.97,"halted":0,"volume":493419,"delay":0,"changeRate":-0.08121827411167509,"floatShares":64520500,"shares":140000000,"eps":-0.432671,"marketStatus":"交易中","change":-0.16,"latestTime":"10-12 15:11:19 EDT","open":1.95,"high":1.95,"low":1.77,"amount":909376.9406604001,"amplitude":0.091371,"askPrice":1.82,"askSize":3356,"bidPrice":1.81,"bidSize":1392,"shortable":0,"etf":0,"ttmEps":-0.432671,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":1.97,"preHourTrading":{"tag":"盘前","latestPrice":1.94,"preClose":1.97,"latestTime":"07:41 EDT","volume":1,"amount":1.94,"timestamp":1791805270880,"change":-0.03,"changeRate":-0.015228,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.97,"latestTime":"19:30 EDT","volume":1216,"amount":2395.52,"timestamp":1791588605015,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.229789},"requestUrl":"/m/hq/s/IKT","defaultTab":"news","newsList":[{"id":"1168616370","title":"Inhibikase Therapeutics公布2026年第二季度财务业绩并重点介绍近期动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1168616370","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168616370?lang=zh_cn&edition=full","pubTime":"2026-08-12 04:02","pubTimestamp":1786478562,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. 于近日披露了其2026年第二季度的财务报告。与此同时，公司还着重强调了近期所取得的一系列关键进展与活跃表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130548574","title":"Inhibikase Therapeutics宣布其药物IKT-001获FDA孤儿药资格认定，用于治疗肺动脉高压","url":"https://stock-news.laohu8.com/highlight/detail?id=1130548574","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130548574?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:03","pubTimestamp":1784808188,"startTime":"0","endTime":"0","summary":"生物制药公司Inhibikase Therapeutics, Inc.近日宣布，其研发的候选药物IKT-001已获得美国食品药品监督管理局授予的孤儿药资格认定，适应症为肺动脉高压。获得孤儿药资格的药物，在获批上市后可能享有七年的市场独占期、税收抵免以及豁免部分申请费用等优惠政策。IKT-001是一种旨在治疗PAH的新型疗法。此次孤儿药资格认定的获得，标志着IKT-001在开发道路上迈出了重要一步，也为Inhibikase Therapeutics在该领域的后续临床开发与商业化进程提供了潜在支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134970199","title":"Inhibikase Therapeutics 宣布通过其市场发行计划出售价值5000万美元的股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1134970199","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134970199?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:03","pubTimestamp":1784030638,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. 已披露，公司将通过其“市场发行”（ATM）计划，出售总额达5000万美元的普通股股份。该融资机制允许公司在公开市场交易时段内，根据市场状况灵活地、分期地发行新股，旨在为公司运营及研发活动提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192022681","title":"Oppenheimer首次覆盖Inhibikase Therapeutics，给予“跑赢大盘”评级及5美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1192022681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192022681?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:23","pubTimestamp":1781094192,"startTime":"0","endTime":"0","summary":"投资机构Oppenheimer已开始追踪研究Inhibikase Therapeutics, Inc.的股票，并在其首份研究报告中，为该公司设定了“跑赢大盘”的评级。分析师同时给出了每股5美元的目标价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144261486","title":"Inhibikase Therapeutics公布2026年第一季度财务业绩并概述近期动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1144261486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144261486?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:02","pubTimestamp":1778616142,"startTime":"0","endTime":"0","summary":"生物制药公司Inhibikase Therapeutics, Inc.近日披露了其截至2026年第一季度的财务报告，同时重点回顾了公司近期的业务进展与关键活动。\n财务业绩与运营亮点的发布，旨在向投资者及市场展示公司在报告期内的经营状况与发展轨迹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167034621","title":"Inhibikase Therapeutics启动首例患者入组，开展Ikt-001治疗肺动脉高压的全球三期IMPROVE-PAH研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167034621","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167034621?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563277,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. (简称Inhibikase) 宣布，其针对肺动脉高压（PAH）的创新疗法Ikt-001，已在全球三期临床试验IMPROVE-PAH中完成首例患者入组。这一重要进展标志着该药物临床开发进入关键阶段，有望为肺动脉高压患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518327836","title":"Inhibikase Therapeutics, Inc.股价拉升13.07% 市值跌214.62万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518327836?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:39","pubTimestamp":1741613989,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时39分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速上涨13.07%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213949a26a27d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213949a26a27d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948892","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.76%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948892?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:36","pubTimestamp":1741185387,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时36分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅上涨5.76%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223628a260c929&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223628a260c929&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637316","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大涨8.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516637316?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:57","pubTimestamp":1741013868,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时57分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅上涨8.91%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257489637b382&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257489637b382&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514373398","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大涨7.69%报2.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373398","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514373398?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:59","pubTimestamp":1740754746,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时59分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅上涨7.69%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225906abe0f1bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225906abe0f1bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869846","title":"Inhibikase Therapeutics, Inc.盘中异动 大幅拉升6.47%报2.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514869846?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:26","pubTimestamp":1740594413,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时26分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速上涨6.47%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270226539893d64c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270226539893d64c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514201535","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大跌6.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514201535?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:45","pubTimestamp":1740494723,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时45分，Inhibikase Therapeutics, Inc.股票出现波动，股价大幅下跌6.85%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224523abdc81ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224523abdc81ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722779","title":"Inhibikase Therapeutics, Inc.盘中异动 早盘股价大跌9.09%报2.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513722779?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:35","pubTimestamp":1740407759,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时35分，Inhibikase Therapeutics, Inc.股票出现波动，股价急速跳水9.09%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223559a2521583&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223559a2521583&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513158722","title":"Inhibikase Therapeutics, Inc.盘中异动 快速跳水5.21%报3.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513158722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513158722?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:51","pubTimestamp":1740160312,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时51分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速下挫5.21%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015152988e0a95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015152988e0a95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512482759","title":"Inhibikase Therapeutics, Inc.盘中异动 急速拉升6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482759","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512482759?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:55","pubTimestamp":1739984121,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时55分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅上涨6.15%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200055229628e44c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200055229628e44c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512614891","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.53%报2.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512614891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512614891?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:28","pubTimestamp":1739892524,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时28分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速上涨5.53%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328449627a274&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182328449627a274&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511613831","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.38%报2.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511613831?lang=zh_cn&edition=full","pubTime":"2025-02-15 01:36","pubTimestamp":1739554601,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日01时36分，Inhibikase Therapeutics, Inc.股票出现异动，股价大幅拉升5.38%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215013641abcf2e26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215013641abcf2e26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510376115","title":"HC Wainwright & Co.：下调Inhibikase Therapeutics(IKT.US)评级，由买入调整至中性评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510376115","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510376115?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:44","pubTimestamp":1739364291,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：下调Inhibikase Therapeutics(IKT.US)评级，由买入调整至中性评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12204448120549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510980638","title":"Inhibikase Therapeutics, Inc.盘中异动 股价大涨5.11%报2.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510980638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510980638?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:40","pubTimestamp":1739209200,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时40分，Inhibikase Therapeutics, Inc.股票出现波动，股价急速上涨5.11%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021101400198809cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021101400198809cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IKT","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509269427","title":"Inhibikase Therapeutics, Inc.盘中异动 临近午盘快速跳水5.10%报2.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509269427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509269427?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:41","pubTimestamp":1738946511,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时41分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速下挫5.10%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208004151abc6475f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208004151abc6475f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IKT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibikase.com","stockEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.1826},{"period":"3month","weight":-0.0343},{"period":"6month","weight":0.1588},{"period":"1year","weight":0.1867},{"period":"ytd","weight":-0.039}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibikase Therapeutics, Inc.于2010年6月3日作为特拉华州的一家公司注册成立。他们是一家临床阶段的制药公司，开发改变心肺疾病（即肺动脉高压）病程的疗法，其中涉及通过III型受体酪氨酸激酶（包括血小板衍生生长因子受体和一种称为“c-Kit”的干细胞因子受体）的异常信号传导。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.188996},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.015653},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.007517},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.118796},{"month":5,"riseRate":0.5,"avgChangeRate":0.028188},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.167248},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049549},{"month":8,"riseRate":0.666667,"avgChangeRate":0.027088},{"month":9,"riseRate":0,"avgChangeRate":-0.140046},{"month":10,"riseRate":0.333333,"avgChangeRate":0.057555},{"month":11,"riseRate":0.8,"avgChangeRate":0.007082},{"month":12,"riseRate":0.6,"avgChangeRate":0.075508}],"exchange":"NASDAQ","name":"Inhibikase Therapeutics, Inc.","nameEN":"Inhibikase Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibikase Therapeutics, Inc.(IKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibikase Therapeutics, Inc.,IKT,Inhibikase Therapeutics, Inc.股票,Inhibikase Therapeutics, Inc.股票老虎,Inhibikase Therapeutics, Inc.股票老虎国际,Inhibikase Therapeutics, Inc.行情,Inhibikase Therapeutics, Inc.股票行情,Inhibikase Therapeutics, Inc.股价,Inhibikase Therapeutics, Inc.股市,Inhibikase Therapeutics, Inc.股票价格,Inhibikase Therapeutics, Inc.股票交易,Inhibikase Therapeutics, Inc.股票购买,Inhibikase Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibikase Therapeutics, Inc.(IKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibikase Therapeutics, Inc.(IKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}